💡Möglicher neuer Ansatz gegen #Bauchspeicheldrüsenkrebs: Wie eine #CharitéBerlin-Studie jetzt zeigt, führt die gleichzeitige Blockade zweier voneinander abhängiger „Zahnrädchen“ in der Krebszelle zur Hemmung des Tumorwachstums – zumindest im Tiermodell.👉charite.de/forschung/paper_s…
Early View | Haematologica haematologica.org/article/vi…
Finally first results from our Phase 1 TCR study targeting MAGE-A1 in myeloma!
Hopefully more to come in advanced solid tumors where need for innovative (cellular) therapies is still HUGE.
Engineering a mouse model of #autoimmunity, researchers at @ChariteBerlin have made strides in understanding the basis of a mysterious and rare autoimmune disorder named STAT3GOF syndrome and identified sex-specific differences in the disorder. @lab_kellerscim.ag/60n
Researchers generated a new mouse model of #STAT3GOF syndrome that can recapitulate the IL-6-gp130-STAT3 pathway and multi-organ autoimmunity—addressing the lack of reliable animal models for this rare autoimmune condition. @lab_keller@ChariteBerlinscim.ag/5Xp
CIAO @_WolfLab 🤍
Today we say goodbye to Anneli and Elmar after more than a decade in the institute. Both of you shaped our institute and the science done @Uni_WUE! We wish you all the best for your new adventure @kieluni!
Check out our recent publication in EMBO Mol Med:
Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response
embopress.org/doi/full/10.15…
In Annals of Oncology, results from the German 🇩🇪 #PrecisionMedicine 🧬🎯💊 NCT/DKTK MASTER trial inform on the association of cancer perdisposing genes and rare cancer
annalsofoncology.org/article…
It's not all about #ubiquitin: Listen to Uta Demel from @lab_keller@MDC_Berlin how inhibition of SUMOylation leads to increased antigen presentation and T-cell activation
A team of researchers from #CharitéBerlin reveal in @jclinicalinvest how cancer cells can evade immunosurveillance. A cellular signaling pathway activated as part of this process may offer a new target for more effective cancer immunotherapy treatments. jci.org/articles/view/152383
Important preclinical study to advance tumor-specific adoptive T cell therapy for patients with MYD88 mutant lymphoma. Congratulations to Antonia Busses group jitc.bmj.com/content/9/7/e00…
Sorry, für heute muss ich erst einmal weg. Ich bin echt enttäuscht und fassungslos zugleich. Mit Beleidigungen kann ich umgehen, aber einige Wortmeldungen sind für mich echt harter Tobak.
After 20 years of preliminary research in the labs of @MDC_Berlin & #CharitéBerlin, a new T-cell immunotherapy against #MultipleMyeloma is now in clinical trials. The innovative treatment is designed to teach the immune system to fight the cancer cells. charite.de/en/service/press_…